Eltrombopag

Generic Name
Eltrombopag
Brand Names
Promacta, Revolade
Drug Type
Small Molecule
Chemical Formula
C25H22N4O4
CAS Number
496775-61-2
Unique Ingredient Identifier
S56D65XJ9G
Background

Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...

Indication

Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.

Associated Conditions
Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia
Associated Therapies
First-line Therapy

Outcomes in Bone Marrow Aplasia.

Phase 3
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-07-10
Last Posted Date
2024-07-10
Lead Sponsor
Assiut University
Target Recruit Count
3
Registration Number
NCT06493981

The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP

First Posted Date
2024-06-28
Last Posted Date
2024-06-28
Lead Sponsor
Yunfeng Cheng
Target Recruit Count
126
Registration Number
NCT06479291
Locations
🇲🇴

Dr. Stanley Ho Medical Foundation, Macau, Macau

🇨🇳

Shanghai Jinshan Hospital, Shanghai, Shanghai, China

🇨🇳

Wusong Hospital, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

and more 4 locations

Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease

First Posted Date
2024-06-14
Last Posted Date
2024-06-17
Lead Sponsor
Tongji Hospital
Target Recruit Count
52
Registration Number
NCT06458803

Eltrombopag for Treatment of Fanconi Anemia

Phase 2
Completed
Conditions
Interventions
First Posted Date
2023-09-21
Last Posted Date
2023-09-21
Lead Sponsor
Julian Sevilla
Target Recruit Count
8
Registration Number
NCT06045052
Locations
🇪🇸

Hospital Infantil Universitario Niño Jesús (HIUNJ), Madrid, Spain

Immune Thrombocytopenia Management in Adults

First Posted Date
2023-05-16
Last Posted Date
2023-05-16
Lead Sponsor
Nahda University
Target Recruit Count
467
Registration Number
NCT05861297
Locations
🇪🇬

EL-Kasr elineiy, Cairo, Egypt

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

First Posted Date
2022-12-16
Last Posted Date
2024-12-12
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
150
Registration Number
NCT05653219
Locations
🇺🇸

Yuma Regional Medical Center, Yuma, Arizona, United States

🇺🇸

Community Cancer Institute, Clovis, California, United States

🇺🇸

Compassionate Care Res Group Inc, Fountain Valley, California, United States

and more 21 locations

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

First Posted Date
2022-10-18
Last Posted Date
2024-07-26
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
157
Registration Number
NCT05583838
Locations
🇨🇳

The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

🇨🇳

the Second Hospital of HeBei Medical University, Shijiazhuang, Hebei, China

🇨🇳

North China University of Science and Technology Affiliated Hospital, Tangshan, Heibei, China

and more 14 locations

The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

First Posted Date
2022-06-30
Last Posted Date
2023-11-24
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
96
Registration Number
NCT05438875
Locations
🇨🇳

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

🇨🇳

Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

🇨🇳

Department of Hematology, Beijing Hospital, Beijing, China

and more 2 locations

Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2022-05-11
Last Posted Date
2022-05-11
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
150
Registration Number
NCT05369377
Locations
🇨🇳

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath